VVA

Knight Therapeutics Reports First Quarter 2024 Results

Retrieved on: 
星期四, 五月 9, 2024
Knight, DLBCL, News, ITP, Health maintenance organization, Hot, Vaginal discharge, Depreciation, Thrombocytopenia, Stomach, Inventory, Collection, Trial of the century, ASCT, Lymphoma, Patient, Acquisition, VVA, IAS, Menopause, Lenalidomide, Absorption, Blue balls, Bookkeeping

Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.

Key Points: 
  • Inventories: As at March 31, 2024, inventories were at $95,400, an increase of $3,566 or 4%.
  • Accounts payable and accrued liabilities: As at March 31, 2024, accounts payable and accrued liabilities were $94,711, an increase of $4,094 or 5%.
  • Cash, cash equivalents and marketable securities: As at March 31, 2024, Knight had $181,859 in cash, cash equivalents and marketable securities, an increase of $20,034 or 12% compared to December 31, 2023.
  • Knight will host a conference call and audio webcast to discuss its first quarter ended March 31, 2024, today at 8:30 am ET.

Eaton’s Mobility Group Chosen to Supply Electromechanical Variable Valve Actuation Technology to Great Wall Motor

Retrieved on: 
星期二, 四月 23, 2024
Other Manufacturing, Alternative Vehicles, Fuels, EV, Electric Vehicles, Vehicle Technology, Automotive, General Automotive, Engineering, Automotive Manufacturing, Other Automotive, Manufacturing, Lorenzon, Map, Torque, EMAS, Environment, Multimedia, VVA, Quality of life, Great Wall of China, Hydraulic machinery

View the full release here: https://www.businesswire.com/news/home/20240423118914/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240423118914/en/
    Eaton’s electromechanical actuation system (EMAS) can be easily integrated into a valvetrain and the cylinder head space and controlled by a simple electric actuator.
  • (Photo: Business Wire)
    “Emissions regulations are driving the adoption of new technologies by our global customers,” said Alessio Lorenzon, global engineering manager, Valves, Eaton’s Mobility Group.
  • “We’re proud to supply Great Wall with our variable valve actuation technology which, in combination with vehicle hybridization, will improve fuel economy in their newest hybrid passenger vehicle lineup.”
    The Eaton EMAS is a discrete valvetrain-based technology that allows manufacturers to select the intake lift that best fits the engine map.
  • When the engine requires maximum performance, the system switches to the longer valve event, delivering the highest output possible.

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
星期四, 三月 28, 2024
Cream, Dysmenorrhea, Patient, History, Bacteria, G&A, Vaginal discharge, IND, Bayer, Human development, Investment, Diclofenac, NSAID, Menstruation, Research, Hormone, Bacterial vaginosis, P-value, Webcast, SAN, NIH, Trial of the century, Pleasure, Woman, Breast cancer, Safety, Pharmacokinetics, Food, Development, Menopause, Nonsteroidal anti-inflammatory drug, HR, ARPA, VVA, Tamoxifen, FDA, Attention, CRADA, Female, Dyspareunia, Ecosystem, NICHD, Bangladesh Technical Education Board

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada

Retrieved on: 
星期四, 一月 4, 2024
Quality of life, Woman, GUD, Estradiol, Pain, Menopause, Dry, Dyspareunia, Therapy, Vaginal discharge, VVA, Ageing, Common, Health Canada, TSX, Patient, Birth control

MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada.

Key Points: 
  • MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada.
  • “We are very excited about the launch of IMVEXXY®, a new treatment option for postmenopausal women in Canada.
  • Knight and TherapeuticsMD signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to IMVEXXY® (estradiol vaginal inserts).
  • Under the terms of the license agreement related to IMVEXXY® in Canada, Knight will pay TherapeuticsMD sales milestone fees and royalties based upon certain aggregate annual sales of IMVEXXY® in Canada.

Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause

Retrieved on: 
星期四, 十二月 7, 2023
Personal lubricant, Quality of life, Food, Woman, IND, Breast cancer, HR, FDA, Prevalence, Menopause, Syndrome, Dyspareunia, SAN, Inflammation, VVA, History, Tamoxifen, Pharmaceutical industry

With the IND clearance from the FDA, Daré can begin planning for an anticipated Phase 2 randomized, double-blinded, placebo-controlled, dose-finding clinical study of DARE-VVA1.

Key Points: 
  • With the IND clearance from the FDA, Daré can begin planning for an anticipated Phase 2 randomized, double-blinded, placebo-controlled, dose-finding clinical study of DARE-VVA1.
  • VVA is an inflammation and thinning of the vaginal epithelium due to chronic hypo-estrogenism, which is the reduction in levels of circulating estrogen.
  • Typical symptoms include vaginal dryness, itching, burning, and painful intercourse (dyspareunia), adversely impacting quality of life.
  • Products containing estrogen are commonly used to treat VVA but some women cannot or choose not to use these products, including those with a history of hormone-receptor positive (HR+) breast cancer.

Azure Biotech Announces Educational Initiative to Create Awareness of Unmet Women’s Menopausal Medical Issue

Retrieved on: 
星期三, 八月 30, 2023
Woman, Vaginal discharge, VVA, Pharmaceutical industry

RIVER VALE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Azure Biotech, Inc., a privately held women’s health company that is developing novel formulations of lasofoxifene for vulvovaginal atrophy (VVA), launches an educational campaign to support women with this underserved menopausal health condition affecting millions of women.

Key Points: 
  • RIVER VALE, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Azure Biotech, Inc., a privately held women’s health company that is developing novel formulations of lasofoxifene for vulvovaginal atrophy (VVA), launches an educational campaign to support women with this underserved menopausal health condition affecting millions of women.

Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, the Journal of the International Menopause Society

Retrieved on: 
星期五, 六月 9, 2023
Survivor, Prevalence, Journal, Vaginal discharge, International Menopause Society, Pharmacokinetics, Woman, History, Trial of the century, Hormone, HR, Investigational New Drug, MD, Patient, Article, SAN, IND, Tamoxifen, Safety, Breast cancer, VVA, Pharmaceutical industry, Birth control, Climacteric

The journal article, “Pharmacokinetics, safety and preliminary pharmacodynamic evaluation of DARE-VVA1: a soft gelatin capsule containing tamoxifen for the treatment of vulvovaginal atrophy,” was published online and will appear in Climacteric, the official journal of the International Menopause Society.

Key Points: 
  • The journal article, “Pharmacokinetics, safety and preliminary pharmacodynamic evaluation of DARE-VVA1: a soft gelatin capsule containing tamoxifen for the treatment of vulvovaginal atrophy,” was published online and will appear in Climacteric, the official journal of the International Menopause Society.
  • The randomized, double-blind, placebo-controlled study was designed to evaluate the pharmacokinetics, safety and pharmacodynamics of DARE-VVA1 in postmenopausal participants with moderate to severe VVA.
  • “The unmet need for an effective non-hormonal treatment for VVA caused by anti-cancer endocrine therapy in patients diagnosed with HR+ breast cancer is undeniable.
  • Daré is conducting activities to support submission of an Investigational New Drug (IND) application and initiation of a Phase 2 clinical study of DARE-VVA1.

Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.

Retrieved on: 
星期四, 六月 8, 2023
Health, Consumer, Women, Other Health, General Health, Pharmaceutical, Cardiology, Dyspareunia, BSE, Partnership, Vaginal discharge, Vulvar Crohn's disease, Woman, Multimedia, Medication, Orange Book, Acquisition, Lacerum, Patent, Menopause, VVA, Pharmaceutical industry, Avia, EU

Cosette Pharmaceuticals, Inc. ("Cosette"), a US-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, has completed the acquisition of the global rights to Intrarosa® from Endoceutics, Inc., a subsidiary of Endorecherche, Inc.

Key Points: 
  • Cosette Pharmaceuticals, Inc. ("Cosette"), a US-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, has completed the acquisition of the global rights to Intrarosa® from Endoceutics, Inc., a subsidiary of Endorecherche, Inc.
  • The transaction includes 108 issued and pending patents across the globe with the latest expiring in 2033 including 3 Orange Book listed patents.
  • View the full release here: https://www.businesswire.com/news/home/20230608005297/en/
    Apurva Saraf, President and CEO of Cosette stated, “This transformative acquisition further strengthens Cosette’s commitment to women’s health with a patent protected, novel drug formulation.
  • In partnership with MSH Pharma Inc., Cosette will leverage its unique commercial and manufacturing capabilities to ensure continued patient access to Intrarosa®.

Eaton to display innovative emission-reduction technologies at Auto Shanghai

Retrieved on: 
星期二, 四月 11, 2023
Automotive, Vehicle Technology, Technology, Engineering, Sustainability, Automotive Manufacturing, Logistics, Supply Chain Management, Manufacturing, General Automotive, Environment, Trucking, Green Technology, Other Automotive, Alternative Energy, Energy, Transport, Other Technology, Performance & Special Interest, Fleet Management, EV, Electric Vehicles, Cylinder, Partnership, Eaton, Hydrogen, Auto Shanghai, Original equipment manufacturer, Quality of life, Multimedia, Temperature, Nitrogen, CDA, NOx, Sanitation, CO2, SCR, VVA, Gasoline, Heating, ventilation, and air conditioning, Renewable energy

View the full release here: https://www.businesswire.com/news/home/20230403005924/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230403005924/en/
    Eaton’s cylinder deactivation and late intake valve closing technologies can reduce harmful emissions in diesel-powered commercial vehicles.
  • (Photo: Business Wire)
    Diesel engine emissions regulations are driving development of new engine and aftertreatment technologies.
  • “VVA technologies play an important role to enable OEMs to meet new regulations,” said Bo Yang, president, Eaton Vehicle Group and eMobility APAC.
  • CDA simultaneously reduces both NOx and CO2, making it more efficient than other technologies that reduce NOx at the expense of CO2.

Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

Retrieved on: 
星期一, 三月 6, 2023
Therapy, Mutation, Breast, AIS, Woman, Lasofoxifene, ESR1, Memorial Sloan Kettering Cancer Center, Dry, International Society, Menopause, Patient, ESMO, Progression-free survival, European Society for Medical Oncology, Breast cancer, Congress, VAS, Pain, Oncology, Cyclin-dependent kinase 4, VVA, Vua tiếng Việt, Fulvestrant, Vaginal discharge, Irritation, Birth control, Dietary supplement

Top-line data for ELAINE 1, which began enrollment in September 2019, were shared in September at the European Society for Medical Oncology (ESMO) Congress 2022.

Key Points: 
  • Top-line data for ELAINE 1, which began enrollment in September 2019, were shared in September at the European Society for Medical Oncology (ESMO) Congress 2022.
  • This secondary analysis aimed to investigate changes in vaginal/vulvar symptoms with lasofoxifene versus fulvestrant, as lasofoxifene improved symptoms of vulvovaginal atrophy (VVA) in two previous Phase 3 studies among postmenopausal women with moderate to severe VVA.
  • Vaginal/vulvar symptoms were evaluated in an exploratory analysis using the vaginal (VAS) and vulvar (VuAS) assessment scales, instruments validated in breast cancer patients to assess dryness, soreness, irritation, and pain.
  • “We look forward to further investigating lasofoxifene’s efficacy, as a treatment for metastatic breast cancer with fewer negative side effects that greatly impact patients’ quality of life.”